Table 1. Comparison of clinical data and plasma proteins between patient groups.
| Variable | Control (n = 20) | Diabetes Mellitus (n = 10) | Metabolic Syndrome (n = 10) | TOPCOAT (Intermediate-risk PE) (n = 76) |
|---|---|---|---|---|
| Age | 56.5 ± 14.6 | 57.8 ± 14.2 | 65.1 ± 20 | 55 ± 13.9 |
| Male gender (%) | 11 (55%) | 5 (50%) | 7 (70%) | 46 (61%) |
| Body mass index (kg/m2) | 27.9 ± 8.1 | 31.3 ± 5.7 | 34.7 ± 4.8* | 33.1 ± 9.1* |
| Diabetes Mellitus | 0 | 10 | 0 | 10 |
| Prior venous thromboembolism | 0 | 0 | 0 | 17 |
| Active malignancy | 0 | 0 | 0 | 15 |
| Thrombin time (s) | 18.1 ± 2 | 19.6 ± 1.2 | 19.8 ± 1.7 | 61 ± 47.1* |
| Fibrinogen (mg/dL) | 320.9 ± 54.7 | 350.7 ± 52 | 338 ± 70.7 | 412.5 ± 148.9* |
| α2-antiplasmin† | 102.7 ± 12.3 | 103.2 ± 5.7 | 106.4 ± 6.7 | 99.2 ± 18.2 |
| Plasminogen† | 98.2 ± 16 | 102.3 ± 11.3 | 104.5 ± 13.7 | 109.8 ± 27.2 |
| TAFI† | 107.3 ± 16.9 | 104.3 ± 18.6 | 106.9 ± 18.7 | 99.5 ± 25.7 |
| D-dimer (μg/mL) | 0.447 ± 0.429 | 0.360 ± 0.141 | 0.429 ± 0.307 | 6.592 ± 5.102* |
| PAI-1 (pg/mL) | 1072.3 ± 780.1 | 3457 ± 2518.7* | 4171.3 ± 2177.7* | 2367.5 ± 2212.9* |
*p < 0.05 from one-way ANOVA with Dunnett’s comparison with control
†Units are expressed as percent activity when compared to standardized controls provided by the manufacturer (Stago Diagnostica). Abbreviations: TAFI-thrombin activatable fibrinolysis inhibitor; PAI-plasminogen activator inhibitor. Values are listed as mean ± SD unless otherwise indicated.